TrialBritish journal of clinical pharmacology2017

Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.

Malcolm Boyce et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.